David Townley 🇺🇦 💙

With DRAGEN v4.5, researchers can uncover more with every sequencing run. Built for researchers in rare disease and precision oncology, v4.5 improves variant calling accuracy across challenging sample types and extends insights into difficult-to-map regions of the genome, delivering precision and scalability – even for some of the most ambitious research demands. Explore what's new in DRAGEN v4.5: bit.ly/4epJlmb #Genomics #RareDisease #Multiomics

🎥@illumina NGS is driving better management of multi-drug-resistant tuberculosis. Watch our @BBCStoryWorks & @WHO Healthier Together film on improving detection and treatment in South Africa. See the full story: illumina.com/company/news-c… #YesWeCanEndTB #WorldTBDay2026

More than half of rare disease cases remain unsolved—often because gene–disease links are unknown or extremely rare. Genome-wide Sequencing Ontario is a collaboration between @SickKidsNews and the Children's Hospital of Eastern Ontario, evaluating the use of explainable AI variant interpretation software to rapidly prioritize variants with unprecedented precision. By also sharing data across Canadian labs, they’re helping clarify variants of uncertain significance—improving the prospect of diagnosis for rare disease patients. Read the full story 👇illumina.com/company/news-c…

The insight ecosystem is here. Today on the mainstage at #AGBTGM26, we shared how we are delivering the highest quality insights at the lowest end-to-end cost, with a value that continues to grow over time. Key highlights: 🔸Launch of TruPath™ Genome, unlocking the most comprehensive genome with a stunningly simple workflow 🔸Multiomics breakthroughs, enabling researchers to go beyond the genome     🔸Increasing power on the NovaSeq X through scale, speed, accuracy, and flexibility If you missed us at #AGBTGM26, register here to see the replay: illumina.com/events/webinar…

Today we reveal a groundbreaking roadmap of updates for the NovaSeq X, with advances in output, quality, speed, and flexibility. Our customers are tackling increasingly ambitious projects, and we’re by their side — innovating to take them further. These advancements will unlock the next wave of breakthroughs in human health, while continuing to bring the gold standard in sequencing to new heights. Learn more about how we are delivering even greater value for our NovaSeq X customers: illumina.com/company/news-c…

1 billion cells. One atlas. Today, Illumina introduces the Billion Cell Atlas, creating the most comprehensive map of human disease biology — and unlocking unparalleled speed and scale in AI for drug discovery. The Atlas will help researchers, including founding participants @AstraZeneca, @Merck, and @EliLillyandCo study the effect of switching on and off all 20,000 genes in cells linked to diseases that have been historically difficult to decode. Learn how the Atlas will elucidate the biological pathways behind some of the world’s most devastating diseases: illumina.com/company/news-c… #JPM2026

Live at #ASHG25: Introducing BioInsight—Illumina’s newest business to help researchers and pharma unlock deeper insights from large‑scale multiomic data. Led by SVP & GM Rami Mehio, BioInsight unites Illumina’s strengths—sequencing, data analysis, software & AI. (1/7)

With the newly formed BioInsight business, Illumina is primed to take data-driven discovery to the next level. Join us at #ASHG25 to hear how scalable informatics, AI, and Perturb-seq are transforming human genetics and driving breakthroughs across life sciences. If you can't make it, register for the on-demand webinar: bit.ly/4o7OHo1

The wait for the Illumina 5-base solution is over.​ Accuracy meets simplicity. Get simultaneous genomic and epigenomic insights from one sample through one streamlined assay. Reimagine your workflow: bit.ly/45x6BZB

Illumina Constellation mapped read tech holds the power to simplify the WGS workflow with on-flow-cell prep + novel algorithms—unlocking genomic insights, ultra-long phasing, and improved structural variant detection. See it live at #ASHG25, Booth 1019, and explore the future of genome sequencing: bit.ly/4pZX6LX

🚀 It’s launch day: Illumina Protein Prep is now available for everyone. 9.5k protein targets. All in one panel. Welcome to the cutting edge of NGS-based proteomics. Get the full scoop ➡️ bit.ly/3VucJgx

Powering genetic rare disease diagnostics with #AWS at Hannover Medical School (MHH) The Whole Genome Sequencing (WGS) based genetic diagnostics has re... aws.amazon.com/blogs/publicse…

By compiling whole genome sequencing data from nearly 500K participants alongside phenotypic data, the @uk_biobank is enabling researchers to unlock unprecedented insights into human health, disease, and genetic diversity. Using DRAGEN secondary analysis, researchers identified 1.5 billion variants – data that is now available to pharma partners and researchers worldwide to accelerate drug discovery and advance precision medicine. Read the full @Nature study here: nature.com/articles/s4158…

Enabling Rapid Genomic and Multiomic Data Analysis with @illumina #DRAGEN™ v4.4 on Amazon EC2 F2 Instances aws.amazon.com/blogs/hpc/enab… via @awscloud

Today, we announced a definitive agreement to acquire SomaLogic, the next step in our multiomics journey. With deep proteomics expertise and a history of collaboration with Illumina, this acquisition will strengthen our ability to deliver end-to-end, scalable insights across genomics and proteomics. Read the full press release here: bit.ly/44udkUM

A patient, a mystery, and a race against time. This is the story of Dakota. At 1 year old, Dakota faced life-threatening kidney failure, and her doctors needed answers fast. Through whole-genome sequencing powered by Illumina and accelerated by @AMD's chip technology, they got answers in time to change the outcome. The team at Rady Children’s Institute for Genomic Medicine delivered results in just one day. Dakota is here today because of what happens when science, healthcare, and AI work together. This piece brings that story to life.

Join our upcoming webinar with product expert @ShyamalMehtalia to explore how the latest DRAGEN v4.4 release can help your lab with enhanced genomic analysis. Register now lnkd.in/ggxBTE2R bit.ly/457pt2S

Today, we unveiled PromoterAI, a groundbreaking algorithm that, for the first time at scale, accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. In a study published today in @ScienceMagazine, researchers report a 6% increase in diagnostic yield for rare disease by applying this technology to a large patient cohort—a major step toward improving the diagnostic rate for patients. 🔗 bit.ly/4kehxkT

🚀 Breaking new grounds in genomics! Attend our corporate satellites at #ESHG on May 26th. Learn more: ilmn.ly/3Rv5a7m #Genomic #Sequencing #multiomics #illumina #ESHG2025

DRAGEN v4.4 raises the bar again to make bioinformatics easier than ever. With major accuracy improvements and ready-to-run applications, researchers can get insights faster, no matter how complex the data. Discover what’s new in DRAGEN v4.4: bit.ly/4ddjz1Y